NeuroVentures

NeuroVentures is a specialized venture development firm that builds and manages early-stage biotechnology companies focused exclusively on the neuroscience and central nervous system (CNS) space. Founded by Belden Hull and W.F. Kieschnick, the company identifies novel neuro-technologies and provides both capital and interim executive leadership to advance programs through the development cycle. Its history is marked by the creation of industry-defining companies such as Rinat Neuroscience (acquired by Pfizer), XenoPort (acquired by Arbor Pharmaceuticals), and Neurovance (acquired by Otsuka). Through its unique "venture development" model, the firm has facilitated the commercialization of therapies like Horizant for Restless Legs Syndrome and the clinical progression of assets like centanafadine for ADHD. The firm's portfolio strategy spans diverse therapeutic approaches, including small molecule reuptake inhibitors and monoclonal antibodies targeting chronic pain and neurodegeneration.